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A Formal Synthesis of (3S, 4R) (-)-fermoxetine and (3S, 4R) (-)-paroxetine from Enantioselective Desymmetrisation of N-Benzyl Imides  Ibrahim U Kutama*      Aminu Ahmed      Saudatu C Jaafaru Department of Chemistry, Faculty of Science Kano University of Science and Technology, Wudil, PMB 3244, Kano-Nigeria  Abstract Enantioselective reduction of N-benzyl 4-substituted glutarimides employing oxazaborolidine catalyst 3 derived from cis-1-amino-indan-2-ol occurred in moderate yield and excellent ee. This has led to the formal synthesis of two antidepressants (-)-fermoxetine 1 and (-)-paroxetine 2. Keywords: Enantioselective, desymmetrisation, imides, glutarimides, fermoxetine, paroxetine   Introduction Recently we have reported an efficient strategy of desymmetrisation of a number of N-Bn glutarimides employing an oxazaborolidine catalyst giving access to the corresponding chiral N-Bn 2-piperidinones in good yields and excellent enantioselectivities (Kutama & Jones, 2015). Two of the chiral piperidin-2-ones are used in this work for the formal synthesis of two important antidepressants (-)-fermoxetine 1 and (-)-paroxetine 2. (-)-Paroxetine hydrochloride marketed as Paxil/Seroxat, and (-)-femoxetine are selective serotonin reuptake inhibitors used in the treatment of depression, obsessive compulsive disorder, and panic. (-)-Paroxetine hydrochloride was reported to have generated sales in excess of over $1.0 billion/year (Liu, et. al., 2001, Yu, et. al., 2000). There have been a number of reported syntheses of these two pharmaceuticals showing different ways of enantioselective constructions of the (3S)- and (4R)-stereogenic centres (Kim, M et. al., 2010). These ways include kinetic resolutions (Sugi, K. et. al. 2000, De Gonzalo, G. et. al., 2001), chiral auxiliaries (Amat, M et. al., 1996),  chiral bases (Johnson, T. A. et. al., 2001, 2002), the use of chiral pool (Cossy, J. et. al., 2001), enantioselective catalysis (Senda, T. et. al., 2001, Taylor, M. S and Jacobsen, E. N., 2003) and enzymatic asymmetrisations (Yu, M. S. et. al., 2000).  The desymmetrisation methodology has also been employed as an effective way of constructing these two stereogenic centres in paroxetine by some research groups. Yu et al. employed a porcine liver esterase (PLE) mediated asymmetric desymmetrisation of glutaric acid bis methyl ester (Yu, M. S. et. al., 2000). Liu et al. used desymmetrisation of 3-substituted glutaric anhydride with (S)-methylbenzylamine (Liu, L. T. et. al., 2001) while Ikariya and co-workers (Ikariya, T and co-workers, 2007) and Simpkins and co-workers (Simpkins, S. N and co-workers, 2003) in separate works employed desymmetrisation of glutarimides for the synthesis of (-)-paroxetine. In this work we have reported the enantioselective reduction of N-benzyl 4-substituted glutarimides employing oxazaborolidine catalyst 3 derived from cis-1-amino-indan-2-ol and their subsequent functionalization to the (3S, 4R) chiral lactams as yet another convenient route to the construction of the two important stereogenic centres in these important pharmaceuticals.  Experimental All solvents were obtained dry from a Grubbs dry solvent system and glassware was flame dried and cooled under vacuum before use. 1H and 13C NMR spectra were measured using CDCl3 or DMSO as solvent unless otherwise stated, on a Brüker 250 or 400 MHz machine with an automated sample changer (unless otherwise stated). Chemical shifts for carbon and hydrogen are given on the  scale relative to TMS (tetramethylsilane, δ = 0 ppm). Coupling constants were measured in Hz. 13C NMR spectra were recorded using the JMOD method. Infrared spectra were recorded on a Perkin-Elmer 1600 FT-IR machine using 0.5mm NaCl cells and mass spectra were recorded on a Kratos instrument using electrospray technique unless otherwise stated.   General Procedure for the asymmetric reduction of glutarimides using B-Me catalyst 3 followed by conversion to the corresponding lactam A suspension of (1R, 2S)-cis-amino-2-indanol (0.15 g, 1.00 mmol) in dry toluene (3 cm3) was treated with trimethylboroxine (0.05 cm3, 0.33 mmol) and allowed to stir under nitrogen for 30 mins. Dry toluene (5 cm3) was added and the reaction distilled until approximately 2 cm3 of solvent remained. This procedure was repeated twice after which the final volume of toluene was removed under pressure to give a yellow solid. Dry dichloromethane (5 cm3) was added to give a stock solution of the B-Me catalyst 3. The catalyst (0.5 cm3, 10 mol %) was added to the solution of the glutarimide substrate (1.00 mmol) in dry dichloromethane (30 cm3) followed by a drop-wise addition of BH3.THF (1 cm3, 1.00 mmol). The solution was then allowed to stir at room 
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temperature for 24 hours. The reaction was finally quenched by addition of MeOH (2 cm3) and 1M HCl (2 cm3), extracted with CH2Cl2 (3 × 15 cm3), dried over MgSO4 and filtered. The solvent was evaporated in vacuo to give the crude hydroxy-lactam as a white powder which was immediately re-dissolved in CH2Cl2 (30 cm3) and treated with TFA (1 cm3) and triethylsilane (1 cm3) in CH2Cl2 (5 cm3). This mixture was allowed to stir at rt for 1 h, after which the solution was added to an ice-water mixture (15 cm3) followed by extraction with CH2Cl2 (3 × 15 cm3). The combined organic extracts were washed with saturated NaHCO3 (3 × 15 cm3), dried over MgSO4 and filtered. The solvent was removed in vacuo to give a crude white solid, which was purified via flash column chromatography eluting with EtOAc : petroleum ether (40-60) (7:3).  4(R)-1-(Phenylmethyl)-4-phenylpiperidin-2-one 5 Using glutarimide 4 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid using general procedure above (0.16 g, 60% over 2 steps) Mpt 80 – 82 oC [lit.(T. A. Johnson et. al., 2002) 88 ‒ 90 oC]; α   + 33.0 (c 1.1, CHCl3; 90% ee), lit.(T. Senda et. al., 2001) α   + 35.0 (c 1.1, CHCl3); vmax (ATR) / cm-1  1619, 1494; 1H NMR (400 MHz; CDCl3) δH 1.97 (1H, dtd, J 13.2, 10.8, 6.0, CHH), 2.07 – 2.14 (1H, m, CHH), 2.63 (1H, dd, J 17.5, 11.0, CHH), 2.83 (1H, ddd, J 17.5, 5.2, 2.0, CHH), 3.13 (1H, tdd, J 11.0, 5.2, 3.1, CHPh), 3.26 – 3.37 (2H, m, 2 × CHH), 4.59 (1H, d, J 14.5, NCHH), 4.77 (1H, d, J 14.5, NCHH), 7.21 – 7.39 (10H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 30.3 (CH2), 38.7 (CH), 39.5 (CH2), 46.4 (CH2), 50.0 (CH2), 126.5 (2 × ArCH), 126.8 (ArCH), 127.5 (ArCH), 128.2 (2 × ArCH), 128.6 (2 × ArCH), 128.8 (2 × ArCH), 137.1 (ArC), 143.4 (ArC), 169.3 (C=O); m/z (EI+) 265 (100%, M+ C18H19NO), 174 (12), 131 (32), 104 (230), 131 (32), 91 (70). Chiral HPLC, Lux 3u CELLULOSE-2, 20% IPA in hexane @ 1.0 mL min-1, tR (major) 23.5 min and (minor) 26.1 min. All data are in accordance with literature. (T. A. Johnson et al., 2002, T. Senda et. al., 2001, S.-S. Jin et. al., 2012).  4(R)-1-(Phenylmethyl)-4-(4-fluorophenyl)piperidin-2-one 9 Using glutarimide 8 (0.30 g, 1.00 mmol) the title compound was obtained as a white solid using general procedure above (0.15 g, 54% over 2 steps) Mpt 114 – 116 oC; α + 30.0 (c 1.1, CHCl3; 92% ee), lit. α + 33.0 (c 1.07, CHCl3); vmax (ATR) / cm-1  3071, 2927, 1625, 1601, 1510; 1H NMR (400 MHz; CDCl3) δH 1.87 – 1.97 (1H, m, CHH), 2.07 – 2.10 (1H, m, CHH), 2.57 (1H, dd, J 17.4, 11.0, CHH), 2.83 (1H, dd, J 17.4, 3.4, CHH), 3.09 ‒ 3.14 (1H, m, CH), 3.25 – 3.36 (2H, m, 2 × CHH), 4.57 (1H, d, J 14.5, NCHH), 4.77 (1H, d, J 14.5, NCHH), 7.03 [2H, (AX)2, ArCH], 7.18 [2H, (AX)2, ArCH], 7.28 – 7.38 (5H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 30.3 (CH2), 38.0 (CH), 39.6 (CH2), 46.2 (CH2), 50.0 (CH2), 115.5 (d, J C-F 21.2, 2 × ArCH), 127.5 (ArCH), 128.0 (d, J C-F 7.8, 2 × ArCH), 128.2 (2 × ArCH), 128.7 (2× ArCH), 137.1 (ArC), 139.1 (d, J C-F 3.0, ArC), 161.7 (d, J C-F 245.0, ArC), 169.1 (C=O); m/z (TOF MS ES+) 284.1437 (100%, MH+ C18H19FNO requires 284.1451). Chiral HPLC, CHIRAL PAK IA, 7% IPA in hexane @ 1.0 mL min-1, tR (minor) 38.2 min and (major) 40.0 min. All data are in accordance with literature. (Senda, T. et. al., 2001, Chaubey, N. R. and Gosh, S. K. 2012).   General Procedure for the synthesis of 3-substituted N-Bn-4-phenylpiperidin-2-ones 6 and 10 (Sébastien, B. et. al., 2010)  Diisopropylamine (1.10 cm3, 7.50 mmol) was added to a flask containing dry THF (5.10 cm3) under N2 atmosphere at - 78 oC and stirred gently. n-BuLi (3.80 cm3, 7.50 mmol, 2.0 M in hexane) was added drop-wise and the mixture stirred at - 78 oC for 10 mins to give the LDA stock solution (7.50 mmol / 10 cm3 solution). The LDA (2.00 cm3, 1.50 mmol) from the stock solution was added drop-wise to a solution of the N-benzyl substrate 5 or 9 (0.27 g, 1.00 mmol) in dry THF (5.00 cm3) under N2 atmosphere. The solution was allowed to stir at - 78 oC for 20 mins. Then the electrophile ethyl chloroformate (1.00 equiv.) was slowly added and the mixture stirred at - 78 oC for 2 h, allowed to warm to room temperature slowly and further stirred for 18 h. The reaction was quenched by slow addition of saturated NaHCO3 (10 cm3), concentrated in vacuo and extracted with CH2Cl2 (3 × 20 cm3). The combined organic extracts were dried over MgSO4, filtered and the solvent removed under reduced pressure to give a crude yellow oily solid, which was purified via flash column chromatography eluting with EtOAc : petroleum ether (40-60) (3:7).  (3S, 4R)-1-Benzyl-2-oxo-4-phenylpiperidine-3-ethyl carboxylate 6 Using general procedure above starting with the phenyl lactam 5 (0.38 g, 1.00 mmol) and ethyl chloroformate (0.10 cm3, 1.00 mmol) as the electrophile, a yellow oily solid was obtained which was purified via flash column chromatography eluting with EtOAc : DCM : petroleum ether (2:1:7) to afford the title compound as yellow solid in 10:1 diastereomeric ratio (0.24 g, 71%) Mpt 140 – 142 oC; α   + 3.0 (c 0.1, CHCl3); vmax (ATR) / cm-1  3029, 2929, 2927, 1733, 1635; 1H NMR (400 MHz; CDCl3) Major diastereomer δH 1.12 (3H, t, J 7.1, CH3), 2.00 ‒ 2.11 (2H, m, 2 × CHH), 3.30 (1H, ddd, J 11.0, 5.3, 3.2, CHPh), 3.39 ‒ 3.50 (2H, m, 2 × CHH), 3.66 (1H, 
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d, J 11.0, CHCO), 4.12 (2H, q, J 7.1, CH2), 4.56 (1H, d, J 14.5, NCHH), 4.79 (1H, d, J 14.5, NCHH), 7.22 [2H, (AX)2, ArCH], 7.29 – 7.39 (8H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 14.0 (CH3), 29.3 (CH2), 42.6 (CH), 46.2 (CH2), 50.3 (CH2), 56.5 (CH), 61.2 (CH2), 126.9 (2 × ArCH), 127.3 (ArCH), 127.6 (ArCH), 128.2 (2 × ArCH), 128.7 (2 × ArCH), 128.2 (2 × ArCH), 128.8 (2 × ArCH), 136.7 (ArC), 141.4 (ArC), 166.0 (OC=O), 170.1 (NC=O); m/z (TOF MS ES+) 338.1758 (100%, MH+ C21H24NO3 requires 338.1756).  (3S, 4R)-1-Benzyl-2-oxo-4-(4-fluorophenyl)piperidine-3-ethyl carboxylate 10 Using general procedure above, starting with the 4-(p-fluorophenyl) lactam 9 (0.36 g, 1.00 mmol) and ethyl chloroformate (0.10 cm3, 1.00 mmol) as the electrophile, a yellow oily solid was obtained which was purified via flash column chromatography eluting with EtOAc : DCM : petroleum ether (40-60) (2:1:7) to afford the title compound as yellow solid in 10:1 diastereomeric ratio (0.22 g, 62% ) Mpt 148 – 150 oC; α  + 3.5 (c 0.1, CHCl3); vmax (ATR) / cm-1  2933, 1734, 1640, 1605; 1H NMR (400 MHz; CDCl3) Major diastereomer δH 1.14 (3H, t, J 7.1, CH3), 1.98 ‒ 2.09 (2H, m, 2 × CHH), 3.30 (1H, ddd, J 11.0, 5.4, 2.9, CHPh), 3.39 ‒ 3.49 (2H, m, 2 × CHH), 3.59 (1H, d, J 11.0, CHCO), 4.13 (2H, q, J 7.1, CH2), 4.53 (1H, d, J 14.5, NCHH), 4.81 (1H, d, J 14.5, NCHH), 7.02 [2H, (AX)2, ArCH], 7.18 [2H, (AX)2, ArCH], 7.28 – 7.39 (5H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 14.0 (CH3), 29.4 (CH2), 41.9 (CH), 46.2 (CH2), 50.3 (CH2), 56.7 (CH), 61.3 (CH2), 115.7 (d, J C-F 21.4, 2 × ArCH), 127.6 (ArCH), 128.2 (2 × ArCH), 128.4 (d, J C-F 8.0, 2 × ArCH), 128.7 (2 × ArCH), 136.6 (ArC), 137.1 (ArC), 161.9 (d, J C-F 245.5, ArC), 165.8 (OC=O), 170.0 (NC=O); m/z (TOF MS ES+) 356.1645 (100%, MH+ C21H23FNO3 requires 356.1662).  (3S, 4R)-1-(Phenylmethyl)-3-(hydroxymethyl)-4-phenylpiperidine 7 BH3.THF (3 equiv.) was added to a solution of the piperidin-2-one 6 (0.22 g, 0.65 mmol) in dry THF. The mixture was heated at reflux for 5 h and cooled to room temperature. Distilled H2O (2 cm3) was slowly added and the resultant solution was extracted with CH2Cl2 (3 × 20 cm3). The combined organic extracts were dried over MgSO4, filtered and the solvent removed under reduced pressure to give the crude material which was purified via flash column chromatography to obtain the title compound as a white solid as a single diastereomer (0.10 g, 55% ) Mpt 106 – 108 oC; α  - 22.2 (c 2.0, CHCl3); vmax (ATR) / cm-1  3063 (broad), 3030, 2926, 2867, 2353, 2277, 1646, 1602; 1H NMR (400 MHz; CDCl3) δH 1.68 – 1.73 (2H, m, 2 × CHH), 2.30 (1H, td, J 11.9, 4.3, PhCH), 2.62 ‒ 2.80 (3H, m, 2 × CHH and CH), 2.39 ‒ 2.98 (1H, m, CHH), 3.03 ‒ 3.06 (1H, m, CHH), 3.17 ‒ 3.24 (2H, m, 2 × CHH), 3.40 (1H, app dd, J 11.0, 3.0, OH), 4.17 (2H, s, NCH2), 7.24 – 7.44 (10H, m, ArCH); 13C NMR (100 MHz; CDCl3) δC 29.4 (CH2), 39.3 (CH), 43.2 (CH), 56.4 (CH2), 59.3 (CH2), 63.2 (CH2), 70.6 (CH2), 126.9 (ArCH), 127.5 (2 × ArCH), 128.3 (2 × ArCH), 128.8 (2 × ArCH), 129.1 (ArCH), 130.3 (ArC), 133.2 (2 × ArCH), 143.2 (ArC); m/z (TOF MS ES+) 282 (100%, MH+ C19H24NO). All data are in accordance with literature (Johnson, T. A. et. al., 2002).   Results and discussions The route leading to the formal synthesis of (3S, 4R) (-)-fermoxetine is represented in Scheme 1. The N-benzyl glutarimide 4 was obtained from benzaldehyde in four steps from a procedure described from our earlier work (Kutama and Simon, 2015). The enantioselective reduction of the glutarimide was carried out successfully using 10 mol% of the oxazaborolidine catalyst 3 at room temperature using BH3.THF as the reducing agent to give the corresponding hydroxy-lactam which was further reduced to give the corresponding lactam 5 by reaction with Et3SiH / TFA in 60% yield (over 2 steps) and 90% ee (Kutama and Simon, 2015). The C-3 enantioselective functionalization of N-Bn lactam 5 was successfully achieved by first treating the lactam with LDA for 30 minutes and quenching with ethyl chloro formate as the electrophile to obtain the carboxylate intermediate 6 in 71% yield and 10:1 dr. Subsequent borane reduction of the carboxylate compound gave the alcohol 7 in 55% yield as a single diastereomer (Scheme 1). The alcohol intermediate 7 could be converted to (-)-femoxetine 1 in four steps by the method of Johnson, T. A  (Johnson, T. A et al., 2002).  
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. HCl  Scheme 2. Formal synthesis of (3S, 4R) (-)-paroxetine 2  Conclusion In conclusion, a formal synthesis of two important antidepressants (3S, 4R)-(-)-femoxetine and (3S, 4R)-(-)-paroxetine from enantioselective desymmetrisation of imides and their subsequent functionalization to install the 
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